REHOVOT, Israel, Aug. 2, 2022
/PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a
leading computational biology company aiming to revolutionize
life-science product development across several market segments,
announced today that it will release its financial results for the
second quarter of 2022 on Wednesday, August
31, 2022.
On the day of the announcement, Company management will host a
conference call to discuss the results at 9:00 AM Eastern time, 4:00
PM Israel time.
To access the conference call, please dial +1-888-281-1167 toll
free from the United States, or
+972-3-918-0609 internationally. Access to the call will also be
available via live webcast through the Company's website at
www.evogene.com.
A replay of the conference call will be available approximately
two hours following the completion of the call. To access the
replay, please dial +1-888-326-9310 toll free from the United States, or +972-3-925-5901
internationally. The replay will be accessible through September 2, 2022, and an archive of the webcast
will be available on the webcast link for the following twelve
months.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE:
EVGN) is a computational biology company aiming to revolutionize
the development of life-science based products by utilizing cutting
edge technologies to increase probability of success while reducing
development time and cost. Evogene established three unique
technological engines – MicroBoost AI, ChemPass AI
and GeneRator AI – leveraging Big Data and Artificial
Intelligence and incorporating deep multidisciplinary understanding
in life sciences. Each technological engine is focused on the
discovery and development of products based on one of the following
core components: microbes (MicroBoost AI), small molecules
(ChemPass AI), and genetic elements (GeneRator AI). Evogene uses
its technological engines to develop products through subsidiaries
and with strategic partners. Currently, Evogene's main
subsidiaries utilize the technological engines to develop novel
products as follows: human microbiome-based therapeutics by Biomica
Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by
AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd.
For more information, please visit: www.evogene.com.
Investor Relations Contact:
Lital Mamon
Head of Marketing and PR
E: IR@evogene.com
T: +972-8-931-2097
Kenny Green
Investor Relations
E: IR@evogene.com
T: +1 212 378 8040
Logo -
https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-financial-results-and-earnings-announcement-schedule-for-the-second-quarter-of-2022-301597792.html
SOURCE Evogene